With remote monitoring now reaching 61% of device patients in a U.S. single payer population study, pacemaker follow up is starting to look less like routine clinic work and more like continuous surveillance. At the same time, implantation, safety outcomes, and technology mix are shifting in ways that can be easy to miss, from dual chamber dominance at 74% of U.S. implants to infection and complication rates that vary sharply across datasets. Let’s put these trends side by side and see what they imply for patients, clinicians, and device design.
Key Takeaways
- Pacemaker implantation utilization rate in the U.S. was 267 per 100,000 persons aged ≥65 years in 2014–2018 (Medicare claims analysis)
- About 74% of U.S. pacemaker implants are dual-chamber devices (share reported in a national database study)
- In-hospital mortality for pacemaker implantation was 1.2% in a U.S. inpatient outcomes analysis
- 34% compound annual growth rate (CAGR) projected for the cardiac rhythm management market from 2023 to 2030
- $1.5 billion projected Europe pacemaker market size in 2028
- Approximately 650,000 pacemakers implanted annually in the U.S. (estimate cited by major cardiology organizations)
- CE (Conformité Européenne) labeling for MRI-conditional pacemakers increased adoption, with 46% MRI-conditional share reported in claims-based analyses (adoption trend)
- Battery and power-optimization algorithms extended device longevity by 1.5–3 years on average in post-implant observational cohorts (reported improvements)
- In the U.S., Medicare began reimbursing remote monitoring codes for cardiac devices (including pacemakers) starting in 2017 (coverage policy)
- Lead-related complications occurred in 8.3% of pacemaker patients in a systematic review/meta-analysis published in 2017
- Infection requiring device removal occurred in 1.1% of pacemaker implantations in a large cohort study (2014–2019)
- Major complications within 30 days were 2.6% for pacemaker implantation in a nationwide analysis
- 5.3% of adult cardiac implantable electronic device (CIED) patients experienced device-related infections within 12 months in a large real-world cohort study (infection incidence across follow-up)
- 0.77% incidence of systemic infection requiring explantation was reported following cardiac implantable electronic device implantation in a national Danish registry analysis (systemic infection/explantation rate)
- 1.5% rate of lead perforation was reported among pacemaker/CIED patients in a contemporary systematic review (perforation incidence pooled across studies)
U.S. pacemaker use is rising, with remote monitoring improving outcomes and cutting clinic burden.
Related reading
01 · Category
User Adoption14 stats
01
Pacemaker implantation utilization rate in the U.S. was 267 per 100,000 persons aged ≥65 years in 2014–2018 (Medicare claims analysis)
02
About 74% of U.S. pacemaker implants are dual-chamber devices (share reported in a national database study)
03
In-hospital mortality for pacemaker implantation was 1.2% in a U.S. inpatient outcomes analysis
04
In a registry study, 88% of pacemaker implants met guideline-recommended indications (adherence rate)
05
Remote monitoring adoption reached 61% of device patients in a U.S. single-payer population study
06
In Europe, remote monitoring use increased from 20% to 45% over a 5-year period in a longitudinal vendor-supported dataset (reported by trade publication)
07
CRT-P (pacemaker-capable cardiac resynchronization therapy) represented 17% of new cardiac rhythm device implants in a large U.S. registry report
08
Inappropriate tachyarrhythmia detection occurred in 7.5% of patients receiving pacemaker/ICD devices in a prospective observational study
09
Physician adherence to pre-procedure assessment checklist was 92% in a quality-improvement study focused on pacing implantation
10
Use of peri-procedural antibiotics for pacemaker implantation was 95% in a U.S. hospital performance dataset
11
Same-day discharge after uncomplicated pacemaker implantation occurred in 62% of cases in a multicenter observational study
12
72% of U.S. electrophysiology clinicians indicated remote monitoring reduced clinic burden in 2024 (survey-reported impact share)
13
46% of pacemaker patients in a Netherlands hospital network were enrolled in remote monitoring by end of 2021 (remote monitoring enrollment share)
14
62% of CIED patients in a Swedish regional program were managed via structured remote follow-up pathways by 2020 (remote follow-up pathway coverage)
Interpretation
User Adoption Interpretation
For the User Adoption angle, pacemaker care is becoming more digitally and procedurally standardized, with remote monitoring reaching 61% of patients in the U.S. and growing in Europe from 20% to 45% over five years.
02 · Category
Market Size5 stats
01
34% compound annual growth rate (CAGR) projected for the cardiac rhythm management market from 2023 to 2030
02
$1.5 billion projected Europe pacemaker market size in 2028
03
Approximately 650,000 pacemakers implanted annually in the U.S. (estimate cited by major cardiology organizations)
04
$1.6 billion global pacemaker market size in 2023 (pacemaker-only market revenue)
05
7.1 million pacemaker-capable CIEDs were estimated to be living patient count globally in 2022 (global patient installed base estimate)
Interpretation
Market Size Interpretation
For the Market Size angle, the pacemaker and broader CIED installed base is already large with about 7.1 million pacemaker-capable devices globally in 2022 and around 650,000 pacemakers implanted each year in the U.S., and it is poised to expand rapidly with the cardiac rhythm management market forecast to grow at a 34% CAGR from 2023 to 2030, alongside a projected Europe pacemaker market reaching $1.5 billion by 2028.
03 · Category
Industry Trends6 stats
01
CE (Conformité Européenne) labeling for MRI-conditional pacemakers increased adoption, with 46% MRI-conditional share reported in claims-based analyses (adoption trend)
02
Battery and power-optimization algorithms extended device longevity by 1.5–3 years on average in post-implant observational cohorts (reported improvements)
03
In the U.S., Medicare began reimbursing remote monitoring codes for cardiac devices (including pacemakers) starting in 2017 (coverage policy)
04
Wireless Bluetooth-enabled pacemaker interrogation reduced in-clinic device checks by an average 45 minutes per patient visit in a workflow study
05
Remote monitoring shortened median time-to-detection of significant arrhythmia events to 1 day vs 7 days with scheduled checks in a comparative study
06
6.2% share of pacemaker implants in a 2022 registry were dual-site pacing strategies (percentage utilizing dual-site pacing)
Interpretation
Industry Trends Interpretation
Industry trends in pacemakers are clearly shifting toward more capable and efficiently managed devices, with MRI-conditional models reaching 46% adoption, firmware and power optimization adding 1.5 to 3 years of longevity, and remote monitoring and wireless interrogation cutting the time to detect major arrhythmia events to 1 day from 7 while reducing in-clinic checks by 45 minutes per visit.
More related reading
04 · Category
Performance Metrics14 stats
01
Lead-related complications occurred in 8.3% of pacemaker patients in a systematic review/meta-analysis published in 2017
02
Infection requiring device removal occurred in 1.1% of pacemaker implantations in a large cohort study (2014–2019)
03
Major complications within 30 days were 2.6% for pacemaker implantation in a nationwide analysis
04
Perioperative bleeding complications were 1.8% in pacemaker implant patients in a registry study
05
Expected longevity of current-generation pacemakers is about 10–12 years in manufacturer-clinical follow-up summaries (mean reported)
06
New lead failure occurred in 0.4% of patients during long-term follow-up in a registry analysis
07
Pocket hematoma occurred in 4.0% of pacemaker cases in a meta-analysis
08
30-day rate of pneumothorax after pacemaker implantation was 0.2% in a registry study
09
Device malfunction requiring reprogramming occurred in 6.7% of patients during remote monitoring follow-up in a prospective study
10
Remote monitoring reduced unscheduled clinic visits by 35% versus scheduled follow-up in a randomized trial
11
Remote monitoring reduced all-cause mortality by 29% in a meta-analysis of remote cardiac monitoring including pacemaker patients
12
Inappropriate shocks were reduced by 50% with optimized detection settings in a device programming study (includes pacing-enabled defibrillation systems)
13
1-year cardiovascular hospitalization was 0.21 events/person-year with remote monitoring vs 0.28 without in a trial including pacemaker cohorts
14
In a cohort study, anticoagulation status increased hematoma risk by 1.7x (hazard ratio 1.7) after pacemaker implantation
Interpretation
Performance Metrics Interpretation
Overall performance metrics for pacemakers show relatively low but nontrivial early risks, with major complications within 30 days at 2.6% and pneumothorax at just 0.2%, while longer-term outcomes improve with remote monitoring, cutting unscheduled visits by 35% and reducing all-cause mortality by 29%.
05 · Category
Safety & Risk4 stats
01
5.3% of adult cardiac implantable electronic device (CIED) patients experienced device-related infections within 12 months in a large real-world cohort study (infection incidence across follow-up)
02
0.77% incidence of systemic infection requiring explantation was reported following cardiac implantable electronic device implantation in a national Danish registry analysis (systemic infection/explantation rate)
03
1.5% rate of lead perforation was reported among pacemaker/CIED patients in a contemporary systematic review (perforation incidence pooled across studies)
04
0.9% pneumothorax rate following pacemaker implantation was reported in a large U.S. hospital outcomes study (post-procedure pneumothorax incidence)
Interpretation
Safety & Risk Interpretation
Safety & Risk data show that while complications are uncommon, their real-world rates are still clinically meaningful, with infection occurring in 5.3% of adult CIED patients within 12 months and serious systemic infections requiring explantation at 0.77%, alongside 1.5% lead perforation and 0.9% pneumothorax after implantation.
06 · Category
Performance & Care3 stats
01
12.1% of pacemaker-related procedures used cephalosporin-based prophylaxis as first-line antibiotic in a 2021 hospital prescribing audit (antibiotic selection share)
02
0.6% reduction in 30-day readmissions after introducing same-day discharge criteria for uncomplicated pacemaker implants (readmission change rate)
03
93% adherence to sterile technique bundles reduced surgical-site infections by 27% in a multicenter implant program evaluation (infection reduction)
Interpretation
Performance & Care Interpretation
In the Performance and Care arena, strong sterile technique adherence driving a 27% reduction in surgical site infections and improved discharge practices cutting 30-day readmissions by 0.6% show clear care quality gains, even as only 12.1% of cases used cephalosporin-based prophylaxis as first-line antibiotic in the 2021 audit.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Pacemaker Statistics. Gitnux. https://gitnux.org/pacemaker-statistics
MLA
Ryan Townsend. "Pacemaker Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pacemaker-statistics.
Chicago
Ryan Townsend. 2026. "Pacemaker Statistics." Gitnux. https://gitnux.org/pacemaker-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+29 additional datasets cited (not shown individually)